653233
2,4-ジクロロ-5-フルオロピリミジン
97%
ログインで組織・契約価格をご覧ください。
この商品について
実験式（ヒル表記法）:
C4HCl2FN2
CAS番号:
分子量:
166.97
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
スキップする
製品名
2,4-ジクロロ-5-フルオロピリミジン, 97%
InChI
1S/C4HCl2FN2/c5-3-2(7)1-8-4(6)9-3/h1H
SMILES string
Fc1cnc(Cl)nc1Cl
InChI key
WHPFEQUEHBULBW-UHFFFAOYSA-N
assay
97%
form
solid
mp
37-41 °C (lit.)
functional group
chloro
fluoro
Quality Level
1 of 4
当該品目 | 684864 | 679089 | 703982 |
|---|---|---|---|
| assay 97% | assay 97% | assay 97% | assay 97% |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| form solid | form liquid | form solid | form solid |
| mp 37-41 °C (lit.) | mp - | mp 66-70 °C | mp 35-41 °C |
| functional group chloro | functional group chloro, fluoro | functional group chloro | functional group fluoro, nitrile |
Application
2,4-Dichloro-5-fluoropyrimidine can be used as a starting material to synthesize:
- 5-fluoropyrimidine-2-carboxamides and 5-fluoropyrimidine-4-carboxamides as potential kinase inhibitors.[1]
- A series of 2,4-diamino-5-fluoropyrimidine derivatives as potential protein kinase Cθ inhibitors.[2]
- 2,4-Bisanilinopyrimidine derivatives as potential aurora kinases inhibitors.[3]
- 5-fluoro-N,N-bis(4-methoxyphenyl)-2,4-pyrimidinediamine by reacting with p-methoxy aniline in the presence of DIPEA.[3]
- 2-chloro-5-fluoro-4-(4-fluorophenyl)pyrimidine by Suzuki coupling reaction in the presence of (4-fluorophenyl)boronic acid triphenylphosphine, and palladium(II) acetate catalyst.[4]
- 5-fluoro-2-(piperidin-4-yloxy)pyrimidin-4-amine, a scaffold, which is used in the preparation of potent deoxycytidine kinase inhibitors.[5]
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Dam. 1 - Skin Corr. 1B - Skin Sens. 1A
保管分類
8A - Combustible corrosive hazardous materials
wgk
WGK 3
flash_point_f
222.8 °F - closed cup
flash_point_c
106 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Ignacio Aliagas-Martin et al.
Journal of medicinal chemistry, 52(10), 3300-3307 (2009-05-01)
The two major Aurora kinases carry out critical functions at distinct mitotic stages. Selective inhibitors of these kinases, as well as pan-Aurora inhibitors, show antitumor efficacy and are now under clinical investigation. However, the ATP-binding sites of Aurora A and
Design, synthesis, and biological evaluation of a series of novel AXL kinase inhibitors
Mollard A, et al.
ACS Medicinal Chemistry Letters, 2(12), 907-912 (2011)
Practical synthesis of 5-fluoro-2-(piperidin-4-yloxy) pyrimidin-4-amine, a key intermediate in the preparation of potent deoxycytidine kinase inhibitors
Zhang H, et al.
Organic Process Research & Development, 13(4), 807-811 (2009)
Optimization of 2, 4-diamino-5-fluoropyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions and P-gp liability
Kunikawa S, et al.
Bioorganic & Medicinal Chemistry, 23(13), 3269-3277 (2015)
Facile and regioselective synthesis of novel 2, 4-disubstituted-5-fluoropyrimidines as potential kinase inhibitors
Wada H, et al.
Tetrahedron Letters, 53(14), 1720-1724 (2012)
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）